Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

3-1-2021

α-tropomyosin
-tropomyosin gene (TPM3) mutation in an infant with nemaline
myopathy
Sulaiman Almobarak
London Health Sciences Centre

Jonathan Hu
Schulich School of Medicine & Dentistry

Kristopher D. Langdon
University of Calgary

Lee Cyn Ang
Schulich School of Medicine & Dentistry

Craig Campbell
London Health Sciences Centre, craig.campbell@lhsc.on.ca

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Almobarak, Sulaiman; Hu, Jonathan; Langdon, Kristopher D.; Ang, Lee Cyn; and Campbell, Craig, "αtropomyosin gene (TPM3) mutation in an infant with nemaline myopathy" (2021). Paediatrics
Publications. 2742.
https://ir.lib.uwo.ca/paedpub/2742

Received: 8 September 2020
DOI: 10.1002/ccr3.3866

|

Revised: 8 January 2021

|

Accepted: 11 January 2021

CASE REPORT
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Abstract
We report a case of neonatal nemaline myopathy with a de novo TPM3 mutation,
which has been classified as a likely pathogenic mutation. With the expanding use of
genetic testing in congenital myopathies, genotype-phenotype descriptions of novel
variants are important to inform clinical care, diagnosis, genetic counseling, and
management of disease.
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IN TRO D U C T ION

Nemaline myopathies (NEM) are heterogeneous congenital
muscle disorders that cause skeletal muscle weakness and,
in the most severe cases, death in the neonatal period. NEM
due to a α-tropomyosin gene (TPM3) mutations are very rare
conditions with few cases reported. Here, we describe a neonatal patient presenting with early onset of hypotonia and
developmental delay with muscle biopsy showing nemaline

myopathy. Genetic testing identified a likely de novo variant
c.43G > C (p.Asp15His) in the TPM3 gene, which is clinically classified as a likely pathogenic mutation.
Pathogenic mutations in the slow α-tropomyosin gene
(TPM3) have been associated with three distinct histological
entities: nemaline myopathy (NM, NEM1), cap disease (CD),
and congenital fiber-type disproportion (CFTD).1 Recently,
Marttila et al summarized the findings in 35 clinically and
histologically characterized families with 22 different TPM3
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variants and found that majority of the families(30/35) had
missense variants segregating in an autosomal dominant inheritance manner or arising de novo.2 Nemaline myopathies
are heterogeneous congenital muscle disorders that cause
skeletal muscle weakness and, in some cases, death immediately after birth.3 Mild progressive proximal muscular
weakness is the most common manifestation of nemaline
myopathy (NEM).4 In neonates, NEM is rarely reported in
the literature, its diagnosis is difficult to establish and as a result, performing a muscle biopsy is instrumental for the correct diagnosis to be established.5 Generally, NEM incidence
is unknown, although two studies, one in Finland, estimated
the incidence to be 1 in 50 000 live births6, and another study
in an American Ashkenazi Jewish population, estimated an
incidence of 1 per 500, suggesting a genetic founder effect.15
Collectively, NEM account for approximately 20% of all congenital myopathy cases.
We report herein a case of neonatal NEM with a heterozygous de novo variant, c.43G > C (p.Asp15His) in the TPM3
gene within the long arm of chromosome 1 (chromosome
1q21.2), which was recently classified as likely pathogenic,
ACMG category 2, and was also previously observed by
three independent clinical genomics laboratory per ClinVar.
Overall, NEM due to aTPM3 gene mutation are a very rare
condition with few cases reported.
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C L IN ICA L R E P ORT

The patient presented as an 8-month-old boy, who was the
fifth pregnancy of non-consanguineous Canadian (European
descent) parents. The pregnancy was uneventful with normal
fetal movements and amniotic fluid volume; following an
unremarkable delivery, there was no concern of respiratory
distress or swallowing difficulties. He presented with a history of hypotonia, developmental delay, and failure to thrive.
He was severely delayed in motor milestones but appropriate
in social and language development. There was a significant
family history of a paternal first cousin with an undifferentiated muscular dystrophy, the details or diagnosis of which
could not be confirmed. There were no other familial neuromuscular, genetic, or congenital diseases.
The patient had displayed signs of hypotonia since birth,
and at 3 months, he was admitted for failure to thrive. Upon
presentation to the neuromuscular clinic, he continued to
demonstrate difficulty with head movement, including holding up his head. He was, however, able to spontaneously
move all extremities against gravity.
His general examination was normal. On neurological
examination, he was hypotonic with evidence of poor muscle bulk to his extremities, truncal hypotonia, and head lag.
There were no obvious dysmorphic features or evidence of
tongue fasciculations. Sensation appeared intact. He was a

|

1673

reflexic with downgoing toes. His mobility was limited to
side-to-side rolling.
The patient underwent multiple admissions for respiratory difficulties and additional investigations. Given the significant hypoventilation and inability to increase respiratory
effort, the decision was made for the patient to initiate nighttime BiPAP. At age 9 months, he had a tracheostomy placed
and has been stable on intermittent BiPap via tracheostomy.
The creatine kinase (CK) level was normal.
Echocardiography was normal. Sequencing of the SMN1
gene did not yield any pathogenic mutations, and alpha-
Glucosidase DBS(dried blood spot) enzyme test was normal.
EMG and nerve conduction studies demonstrated spontaneous activity in proximal muscles, consistent with possible
myopathy. An MRI of the thigh and pelvic girdle muscles
showed no obvious abnormalities.
The patient underwent a quadriceps skeletal muscle biopsy shown in Figure 1. Histologically, the muscle demonstrated fairly dramatic fiber-
size variability with both
atrophic/hypotrophic (“small”) and hypertrophic fibers seen
(including scattered fiber-splitting; range 3-40 µm). Fibrosis
was increased among both the endomysium and perimysium.
The Gomori trichrome staining revealed numerous subsarcolemmal and sarcoplasmic “red” granules and rods, consistent with nemaline rods, primarily in the small fibers but also
noted in the histologically “normal” fibers. Focally, at least
50% of the small fibers contain nemaline rods.
Enzyme histochemistry demonstrated that the small fibers
were type 1 (ATPase 4.2 and MHC-s immunohistochemistry)
and that the type 2 fibers (and scattered type 1 fibers) were
of relatively normal size. Overall, there was type 2 fiber predominance with many fibers co-expressing both slow (MHC-
s) and fast (MHC-f) myosin heavy chains.
Prominent sarcoplasmic inclusions were noted among the
atrophic fibers on semi-thin Toluidine blue-stained sections.
Ultrastructural analysis demonstrated abundant and robust
Z-line-like electron densities with lattice morphology. These
were seen in highest density among the small fibers, but also
noted among the more “normal” appearing fibers.
Generally, it is thought that in alpha-tropomyosin NEM
cases, the nemaline inclusions are largely restricted to type
1 fibers and that the majority of these fibers are atrophic/
hypotrophic (small).
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M OLECULAR GENETICS

Clinicopathological correlation via genetic testing
(Nemaline myopathy panel, Invitae) initially revealed
three variants of uncertain significance (VUS) identified
in MEGF10, NEB, and TPM3, and all of them were heterozygous. The first was a missense VUS, c.2974G > A
(p.Glu992Lys) identified in MEGF10. The MEGF10
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F I G U R E 1 Skeletal muscle biopsy. A, The well-populated fascicles demonstrated fibre-size variability with both atrophic and hypertrophic
fibres (HPS stain). There were several groups of polygonal atrophic fibres. There was increased perimysial and endomysial fibrosis. B, Gomori
Trichrome demonstrated numerous sarcoplasmic ''red' granules or rods uniformly distributed in the atrophic fibres and patchy in non-atrophic
fibres. C, ATPase 4.2 demonstrated type 1 atrophy/hypotrophy (grouped or single) with the type 2 fibres (ATPase 9.4; D, comprising the majority
of normal diameter fibres. E, Toluidine blue sections revealed prominent dark staining 'inclusions' noted most prominently within the atrophic
fibres but also pale subsarcolemmal and sarcoplasmic "core-like" staining seen in non-atrophic fibres. F, Ultrastructural examination demonstrated
abundant and robust Z-line-like electron densities with a 'lattice' appearance interpreted as nemaline rods.These were seen in highest densities
among the atrophic fibres but also noted among the more 'normal' appearing fibres. Scale bar A-E is 50 µm; F is 4 µm

gene is known to be associated with autosomal recessive
early-onset myopathy, areflexia, respiratory distress, and
dysphagia (EMARDD), but not nemaline rod histology
on muscle biopsy. The second was a synonymous VUS,
c.17619C > T (p.Gly5873=) identified in NEB. The NEB
gene is known to be primarily associated with autosomal
recessive nemaline myopathy 2 (NEM2). The third was
a missense VUS, c.43G > C (p.Asp15His) identified in
TPM3. Importantly, this variant classification has recently
been updated to be likely pathogenic per ClinVar. This
variant was not present in population databases such as
gnomAD. Algorithms developed to predict the effect of
missense changes on protein structure and function (SIFT,
PolyPhen-2,Align-GVGDandMutationTaster) all suggest
that this variant is likely to be disruptive. The TPM3 gene
is associated with autosomal dominant or recessive NEM1
and congenital myopathy with fiber-
type disproportion
(CFTD). Absence of a second causative variant in the autosomal recessive MEGF10 and NEB genes suggested it
is unlikely that these are causative variants. In contrast,

genetic analysis confirmed that neither of the parents were
carriers for the pathogenic TPM3 mutation in peripheral
blood, suggesting a de novo mutation in the affected child
in a gene with known dominant inheritance.
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DISCUSSION

In this case report, we describe an infant with an early-onset
NEM and a morphological phenotype characterized by the
presence of nemaline rods, which was confirmed ultrastructurally. Using next generation sequencing analysis, we
observed a heterozygous missense mutation, c.43G > C
(p.Asp15His), in the TMP3 gene. This mutation was not present in both parents indicating that the mutation has likely
occurred de novo and has been classified as a likely pathogenic mutation associated with autosomal dominant NEM1.
Functional modeling of the mutation would be needed to definitely understand the pathophysiologic implications of this
mutation on TPM3.
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Childhood NEM is associated with a wide range of phenotypes from more benign congenital conditions, which
present early and either progresses slowly or not at all7,8 to
severe weakness and debilitating functional impairment.
The TPM3 gene is one of ten genes (TPM3, NEB, ACTA1,
TNNT1, TPM2, CFL2, KBTBD13, KLHL40, KLHL41, and
LMOD3) currently associated with NEM.9 In contrast to our
case which showed a normal pregnancy history with normal
fetal movements, it has been reported that hydramnion and
decreased fetal movements are the most frequent symptoms
of NEM during pregnancy.5 At birth, the clinical findings
of NEM are inconsistent and nonspecific; however, severe
hypotonia, especially involving the proximal limb muscles and those of the face, neck, and trunk, may be noted.5
Respiratory difficulties can be a prominent and worrisome
finding at birth due to diaphragmatic muscle weakness.4,5In
a paper that studied the clinical and pathological features of
28 Chinese patients with NEM, Yin and colleagues demonstrated that hypotonia was observed in most patients.10 This
is in keeping with our case, which showed signs of hypotonia
since birth, but with the ability to spontaneously move all
limbs in response to external stimuli. Additionally, respiratory problems appear to be a consistent finding at birth due
to diaphragmatic muscle weakness.4,5 In parallel with these
28 cases of NEM,10 the current case showed normal creatine
kinase level. Side-to-side rolling was the most complex volitional motor function achieved in our case and in a similar
case reported by Kiiskiet al.11
In the case reported by Kiiski et al, the Gomori trichrome stain identified red-staining inclusions in several
fibers which were confirmed to be nemaline rods by electron microscopy.11 Additionally, with the modified Gomori
trichrome stain, Tsujihataet al12 found numerous dark red
granular deposits in many fibers. In the current case, and as
judged by myosin and ATPase stains, the small fibers were
of histochemical type 1 and the normal-sized fibers consisting of a mixture of type 2 (predominantly) and type 1, and
the rod bodies were observed in both type 1 and scattered
type 2 fibers.12
Tan P et al13 described a NEM case with a homozygous
nonsense mutation in TPM3 with severe NEM1 phenotype,
showing extremely delayed and impaired motor development,
except for rolling over. This patient showed type 1 fiber hypotrophy, mild predominance of type 2 fibers, and nemaline
bodies were only present in type 1 fibers. In contrast to the
current case, that case showed no feeding problems. Kiiski
et al reported that muscle biopsy showed fiber size and rod
variations in a population of hypotrophic muscle fibers expressing slow myosin, often with internal nuclei, and abnormal immune labeling that revealed many hybrid fibers.11
Family history and clinical evaluation of the parents
helped in establishing a diagnosis in this case. There were
no known cases of muscle disease in the immediate family,
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and the parents' clinical investigations and genetic testing were normal. The possibility of germline mosaicism
in either parent has not been excluded and current literature estimates the recurrence risk for de novo variants as
0.011%-28.5%.14 Genetic counseling is both important and
recommended to advice on future pregnancies as is thorough monitoring with repetitive ultrasound examinations to
assess fetal parameters.
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CONCLUSION

Here, we report a case of neonatal nemaline myopathy with
a heterozygous de novo mutation c.43G > C (p.Asp15His)
in the TPM3 gene, which has been classified as likely pathogenic given the supporting clinical scenario and histological
picture Figure 1.
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